Pharmafile Logo
Pharmafocus logo
Advanced Search

NICE recommends treatment for chronic kidney disease, IgA nephropathy

May 23, 2025
Market & Product Development, Medical Communications, Research and Development IgA nephropathy, National Institute for Health and Care Excellence, Nephrology, kidney disease

The National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending CSL Vifor’s FILSPARI (sparsentan) for …

News
blood_test

CHMP issues positive opinion for Blenrep combinations in relapsed/refractory multiple myeloma

May 23, 2025
Market & Product Development, Medical Communications, Research and Development Blenrep, Committee for Medicinal Products for Human USE, European Medicines Agency, Oncology, multiple myeloma

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion …

News
handshake

Sanofi to acquire Vigil Neuroscience, adding Alzheimer’s disease candidate to early-stage pipeline

May 23, 2025
Mergers and Acquisitions, Research and Development Alzheimer's disease, Neurology, Sanofi, Vigil Neuroscience, neurodegenerative diseases

Sanofi has announced an agreement to acquire Vigil Neuroscience, a biotech company focused on therapies for neurodegenerative diseases. The deal …

News

PL BioScience and DewCell sign LOI to Jointly Develop Artificial Human Platelets for Scalable, Animal-Free Cell Culture Media

May 23, 2025
Research and Development Animal-Free, Artificial Human Platelets, Corporate, DewCell, Haematology, Human Platelet Lysate, Letter of Intent, Oncology, PL Bioscience

PL BioScience and DewCell Biotherapeutics have signed a Letter of Intent (LOI) for the development and supply of artificial human …

News
Press release

Another Day Pharma announces successful Phase II trial results for BZ371A in post-prostatectomy erectile dysfunction 

May 22, 2025
Research and Development Another Day Pharma, Genito-Urinary system, clinical trial, erectile dysfunction, prostate cancer, prostatectomy

First-in-class therapeutic peptide BZ371A confirmed as effective and well-tolerated  20 May 2025. Another Day Pharma Ltd, a company developing innovative …

News
Press release

Tiakis Biotech appoints Christoph Schmidt to supervisory board

May 22, 2025
Research and Development Cardiology, Tiakis Biotech, cardiovascular diseases, pulmonary arterial hypertension

Tiakis Biotech has announced the appointment of Christoph Schmidt to its supervisory board. Based in Kiel, Germany, the clinical-stage biotech …

Appointment

NICE recommends Pfizer’s new once-weekly treatment for haemophilia B on NHS

May 22, 2025
Market Access, Research and Development Haematology, Hympavzi, NHS, NICE, Pfizer, haemophilia B, marstacimab

Walton Oaks, 21st May 2025 – Pfizer Ltd announced today that the National Institute for Health and Care Excellence (NICE) has published final …

News
Press release

Five Facts about mental health

May 21, 2025
Medical Communications, Medical Education, Research and Development European Commission, Pharmacy, Psychiatry, mental health, mental health condition

32% of people suffer from at least one mental health issue, with daily struggles like financial and job insecurity being …

Feature
researchers

Novartis releases new data across oncology and haematology pipelines

May 21, 2025
Research and Development ASCO, EHA, Haematology, Novartis, Oncology, oncology

Novartis has announced it will present new data at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting taking …

News

Slingshot Therapeutics appoints Ed Savory as head of chemistry

May 21, 2025
Research and Development Corporate, Pharmacy, Slingshot Therapeutics, appointment

Slingshot Therapeutics has announced the appointment of Ed Savory as head of chemistry. He will oversee the company’s chemistry strategy …

Appointment

BioPhorum appoints Uwe Buecheler as non-executive director

May 21, 2025
Medical Communications, Research and Development BioPhorum, Corporate, appointment, biopharma, medical communication

BioPhorum has announced the appointment of Uwe Buecheler as a non-executive director to its board. The company brings together leaders …

Appointment

Multiple myeloma treatment approved in Japan

May 21, 2025
Market Access, Research and Development, Sales and Marketing GSK, Japan, Oncology, Orphan Drug Designation (ODD), multiple myeloma

GSK’s Blenrep (belantamab mafodotin) combinations have been approved by Japan’s Ministry of Health, Labour and Welfare for the treatment of …

News

FDA approves Incyte’s new anal cancer treatment

May 20, 2025
Research and Development FDA, Incyte Corporation, Oncology, Orphan Drug Designation (ODD), Zynyz, fast track designation, priority review

The US Food and Drug Administration (FDA) has approved Incyte Corporation’s immunotherapy retifanlimab-dlwr (Zynyz) in combination with carboplatin and paclitaxel to treat …

News

Landmark BioVentures launches spin-off biotech to tackle fibrotic, neoplastic and neovascularised conditions

May 20, 2025
Research and Development Aix-Marseille University, Cardiology, Corporate, Landmark BioVentures, Massalia Therapeutics, Oncology, cardiovascular research, oncology

Landmark BioVentures and researchers at Aix-Marseille University in Marseille, France, have launched Massalia Therapeutics. Marking Landmark’s seventh company, the spin-off …

News

Duck Creek Technologies appoints Tyler Jones as chief marketing officer

May 20, 2025
Business Services, Pharmaceutical Consultancy Services Corporate, Duck Creek Technologies, appointment, chief marketing officer, property and casualty (P&C) insurance

Duck Creek Technologies has appointed Tyler Jones as its new chief marketing officer (CMO). He will lead the company’s global …

Appointment

FDA approves diagnostic tool for MET-targeted lung cancer therapy

May 19, 2025
Research and Development FDA, Oncology, Roche, lung cancer, non-squamous non-small cell lung cancer

The US Food and Drug Administration (FDA) has approved Roche’s VENTANA MET (SP44) RxDx Assay as a diagnostic tool to …

News

Cold plasma therapy shown to be 100% effective against pneumonia-causing bacteria

May 19, 2025
Research and Development Infections and infestations, MRSA, Viromed Medical, intensive care, lung therapy, ventilator-associated pneumonia (VAP)

A breakthrough in lung therapy has been reported by German biotech company Viromed Medical whose cold plasma treatment has demonstrated …

News

Medable unveils oncology trial platform aimed at reducing logistical hurdles

May 16, 2025
Biotech/start-up, Business Services, Research and Development, Sales and Marketing, Technical Consultancy AI, FDA, Medable, Oncology, digital platform, oncology research, oncology trials

Clinical trial technology provider, Medable, has launched a digital platform designed to support oncology clinical trials by addressing growing operational …

News
researchers

Moleculin secures EMA approval to expand acute myeloid leukaemia trial across EU

May 16, 2025
Research and Development Clinical Trial Application (CTA), European Union (EU), FDA, Food and Drug Administration, Moleculin Biotech, Oncology, Orphan Drug Designation (ODD), acute myeloid leukaemia

Moleculin Biotech has received approval from the European Medicines Agency (EMA) to expand its phase 3 ‘MIRACLE’ trial into nine …

News

Hansa Biopharma data demonstrates potential of imlifidase in Guillain-Barré syndrome

May 15, 2025
Research and Development Guillain-Barré Syndrome (GBS), Hansa Biopharma, Immunology, Peripheral Nerve Society (PNS) Annual Meeting, Rare Diseases

Hansa Biopharma will present data from its 15-HMedIdeS-09 phase 2 study of imlifidase for treating Guillain-Barré syndrome (GBS) at the …

News
The Gateway to Local Adoption Series

Latest content

Alto Neuroscience announces new patent for depression treatment

January 15, 2026

Arkin Capital closes $100m fund for pre-clinical and early clinical-stage biotech

January 15, 2026

Bio-Sourcing and Zerion Pharma receive 1.3m euros in funding for joint breast cancer project

January 14, 2026

Biocartis announces breast cancer research collaboration with US Mayo Clinic

January 14, 2026

Blue Earth announces first UK patient received prostate cancer injection

January 13, 2026